Lupin Ltd

(LUPIN)

Lupin's Target Price Increased Amid Positive Outlook - 13 Nov, 2024

KR Choksey has upgraded Lupin's target price to Rs 2,472, citing strong revenue growth and profitability driven by new product launches and an expanding portfolio.

Lupin's Target Price Increased Amid Strong Performance - 12 Nov, 2024

Prabhudas Lilladher has reaffirmed a Buy rating for Lupin, raising the target price to Rs 2,420 due to strong Q2FY25 results and growth prospects in the U.S. market. The company reported a 13% YoY revenue increase and a 41% YoY EBITDA growth, driven by a robust product pipeline and regulatory progress.

Lupin Receives Multiple Upgrades and Target Price Increases - 11 Nov, 2024

Lupin Ltd has received upgrades from HSBC and Prabhudas Lilladher, with target prices raised to ₹2,400 and ₹2,420, respectively. Emkay also maintains a 'Buy' rating with a target of ₹2,750, citing strong Q2 performance and margin expansion.

Lupin Reports Strong Growth in Q2 FY25 - 10 Nov, 2024

Lupin Ltd. reported a 13% revenue increase to Rs 5,672.7 crore and a 74% rise in net profit to Rs 852.6 crore in Q2 FY25. The US business grew 6% YoY, driven by new product launches, despite a sequential dip in sales.

Lupin Reports Strong Q2 Earnings and Growth - 08 Nov, 2024

Lupin Limited's Q2 FY25 results show a 74.1% increase in net profit, driven by robust sales in North America and India. The company also received FDA approval for Raltegravir Tablets, enhancing its market position.

Lupin Reports Strong Q2 Results with Profit Surge - 07 Nov, 2024

Lupin Ltd's Q2FY25 results show a 74% increase in net profit to Rs 852.63 crore, exceeding estimates. Revenue rose 12.6% to Rs 5,672.73 crore, with EBITDA margin expanding to 23.6%. Despite strong performance, stock closed down 2.72% post-announcement.

Lupin Ltd Shares Rise on US Market Stability - 06 Nov, 2024

Lupin Ltd shares increased by 0.58% amid positive developments in the US generics market, with pricing erosion stabilizing, potentially boosting profitability for the company.

Lupin Focuses on Eco-Friendly Inhalers - 28 Oct, 2024

Lupin Limited is developing respiratory inhalers using near-zero global warming potential propellants, aiming to reduce environmental impact while ensuring patient access to effective treatments. This initiative aligns with European regulations and reflects Lupin's commitment to sustainable healthcare innovation.

Lupin Limited Shows Signs of Weakness - 24 Oct, 2024

Lupin Limited is experiencing a downturn after breaking down from a distribution pattern, with recommendations to initiate short positions due to negative sentiment in the pharma index.

Claus Jepsen Appointed President of Lupin's Global Specialty - 21 Oct, 2024

Lupin Limited has appointed Claus Jepsen as President of its Global Specialty Business. Jepsen, formerly with Takeda Pharmaceuticals, brings extensive experience in specialty strategy and portfolio management.

Lupin Launches First Generic Eye Treatment in US - 15 Oct, 2024

Lupin Limited has launched the first generic version of Pred Forte (Prednisolone Acetate) Ophthalmic Suspension in the US, gaining 180-day exclusivity. This move strengthens Lupin's ophthalmic portfolio and is expected to benefit patients with steroid-responsive inflammation. The branded version had estimated annual sales of USD 198 million.